The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy

Molecular Neurobiology

Volumn 53, Issue 7, 2016, Pages 4893-4904

  Zhang, Cheng Cheng ^a   Xing, Ang ^b   Tan, Meng Shan ^b   Tan, Lan ^a,b   Yu, Jin Tai ^b,c  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetics; MAPT; Neurodegeneration; Pathogenesis; Therapy

Indexed keywords

ACETYLCHOLINE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOPEPTIDE; TAU PROTEIN; TELMISARTAN; MAPT PROTEIN, HUMAN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BIOCHEMICAL COMPOSITION; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EPIGENETICS; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; IMMUNOTHERAPY; INHIBITION KINETICS; MAPT GENE; MUTATIONAL ANALYSIS; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TAUOPATHY; ANIMAL; GENE THERAPY; GENETICS; MUTATION; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; GENETIC THERAPY; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MUTATION; NEURODEGENERATIVE DISEASES; TAU PROTEINS; TAUOPATHIES;

EID: 84941334167     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9415-8     Document Type: Review

References (129)

1. Ittner LM, Gotz J (2011) Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12(2):65–72. doi:10.1038/nrn2967
2. Yu JT, Tan L, Hardy J (2014) Apolipoprotein E in Alzheimer's disease: an update. Annu Rev Neurosci 37:79–100. doi:10.1146/annurev-neuro-071013-014300
3. Spillantini MG, Goedert M (2013) Tau pathology and neurodegeneration. Lancet Neurol 12(6):609–622. doi:10.1016/s1474-4422(13)70090-5
4. Spillantini MG, Bird TD, Ghetti B (1998) Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol 8(2):387–402
5. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S et al (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393(6686):702–705. doi:10.1038/31508
6. Rossi G, Bastone A, Piccoli E, Morbin M, Mazzoleni G, Fugnanesi V, Beeg M, Del Favero E et al (2014) Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features. Neurobiol Aging 35(2):408–417. doi:10.1016/j.neurobiolaging.2013.08.004
7. Di Fonzo A, Ronchi D, Gallia F, Cribiu FM, Trezzi I, Vetro A, Della Mina E, Limongelli I et al (2014) Lower motor neuron disease with respiratory failure caused by a novel MAPT mutation. Neurology 82(22):1990–1998. doi:10.1212/wnl.0000000000000476
8. Iyer A, Lapointe NE, Zielke K, Berdynski M, Guzman E, Barczak A, Chodakowska-Zebrowska M, Barcikowska M et al (2013) A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function. PLoS One 8(9), e76409. doi:10.1371/journal.pone.0076409
9. Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E et al (2012) Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet 21(15):3500–3512. doi:10.1093/hmg/dds161
10. Ling H, Kara E, Bandopadhyay R, Hardy J, Holton J, Xiromerisiou G, Lees A, Houlden H et al (2013) TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT. Neurobiol Aging 34(12):2889. doi:10.1016/j.neurobiolaging.2013.04.011, e2885-2889
11. Liang Y, Gordon E, Rohrer J, Downey L, de Silva R, Jager HR, Nicholas J, Modat M et al (2014) A cognitive chameleon: lessons from a novel MAPT mutation case. Neurocase 20(6):684–694. doi:10.1080/13554794.2013.826697
12. Simon-Sanchez J, van Hilten JJ, van de Warrenburg B, Post B, Berendse HW, Arepalli S, Hernandez DG, de Bie RM et al (2011) Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet 19(6):655–661. doi:10.1038/ejhg.2010.254
13. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, Wang L, Zuchner S et al (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74(2):97–109. doi:10.1111/j.1469-1809.2009.00560.x
14. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P et al (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41(12):1308–1312. doi:10.1038/ng.487
15. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T et al (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41(12):1303–1307. doi:10.1038/ng.485
16. Wolfe MS (2012) The role of tau in neurodegenerative diseases and its potential as a therapeutic target. Scientifica 2012:796024. doi:10.6064/2012/796024
17. Goedert M, Jakes R (1990) Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J 9(13):4225–4230
18. Yuzwa SA, Shan X, Macauley MS, Clark T, Skorobogatko Y, Vosseller K, Vocadlo DJ (2012) Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol 8(4):393–399. doi:10.1038/nchembio.797
19. Borghgraef P, Menuet C, Theunis C, Louis JV, Devijver H, Maurin H, Smet-Nocca C, Lippens G et al (2013) Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice. PLoS One 8(12), e84442. doi:10.1371/journal.pone.0084442
20. Graham DL, Gray AJ, Joyce JA, Yu D, O'Moore J, Carlson GA, Shearman MS, Dellovade TL et al (2014) Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology 79:307–313. doi:10.1016/j.neuropharm.2013.11.025
21. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y et al (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67(6):953–966. doi:10.1016/j.neuron.2010.08.044
22. Sultan A, Nesslany F, Violet M, Begard S, Loyens A, Talahari S, Mansuroglu Z, Marzin D et al (2011) Nuclear tau, a key player in neuronal DNA protection. J Biol Chem 286(6):4566–4575. doi:10.1074/jbc.M110.199976
23. Reddy PH (2011) Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res 1415:136–148. doi:10.1016/j.brainres.2011.07.052
24. Villa C, Ghezzi L, Pietroboni AM, Fenoglio C, Cortini F, Serpente M, Cantoni C, Ridolfi E et al (2011) A novel MAPT mutation associated with the clinical phenotype of progressive nonfluent aphasia. J Alzheimers Dis 26(1):19–26. doi:10.3233/jad-2011-102124
25. Magnani E, Fan J, Gasparini L, Golding M, Williams M, Schiavo G, Goedert M, Amos LA et al (2007) Interaction of tau protein with the dynactin complex. EMBO J 26(21):4546–4554. doi:10.1038/sj.emboj.7601878
26. Ronnback A, Nennesmo I, Tuominen H, Grueninger F, Viitanen M, Graff C (2014) Neuropathological characterization of two siblings carrying the MAPT S305S mutation demonstrates features resembling argyrophilic grain disease. Acta Neuropathol 127(2):297–298. doi:10.1007/s00401-013-1229-z
27. Rossi G, Conconi D, Panzeri E, Paoletta L, Piccoli E, Ferretti MG, Mangieri M, Ruggerone M et al (2014) Mutations in MAPT give rise to aneuploidy in animal models of tauopathy. Neurogenetics 15(1):31–40. doi:10.1007/s10048-013-0380-y
28. Alonso Adel C, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K (2004) Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem 279(33):34873–34881. doi:10.1074/jbc.M405131200
29. Deramecourt V, Lebert F, Maurage CA, Fernandez-Gomez FJ, Dujardin S, Colin M, Sergeant N, Buee-Scherrer V et al (2012) Clinical, neuropathological, and biochemical characterization of the novel tau mutation P332S. J Alzheimers Dis 31(4):741–749. doi:10.3233/jad-2012-120160
30. Ishizuka T, Nakamura M, Ichiba M, Sano A (2011) Familial semantic dementia with P301L mutation in the Tau gene. Dement Geriatr Cogn Disord 31(5):334–340. doi:10.1159/000328412
31. Chaunu MP, Deramecourt V, Buee-Scherrer V, Le Ber I, Brice A, Ehrle N, El Hachimi K, Pluot M et al (2013) Juvenile frontotemporal dementia with parkinsonism associated with tau mutation G389R. J Alzheimers Dis 37(4):769–776. doi:10.3233/jad-130413
32. Kouri N, Carlomagno Y, Baker M, Liesinger AM, Caselli RJ, Wszolek ZK, Petrucelli L, Boeve BF et al (2014) Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. Acta Neuropathol 127(2):271–282. doi:10.1007/s00401-013-1193-7
33. Rohrer JD, Paviour D, Vandrovcova J, Hodges J, de Silva R, Rossor MN (2011) Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome. Neurodegener Dis 8(3):149–152. doi:10.1159/000319454
34. Kovacs GG, Pittman A, Revesz T, Luk C, Lees A, Kiss E, Tariska P, Laszlo L et al (2008) MAPT S305I mutation: implications for argyrophilic grain disease. Acta Neuropathol 116(1):103–118. doi:10.1007/s00401-007-0322-6
35. Sharkey FH, Morrison N, Murray R, Iremonger J, Stephen J, Maher E, Tolmie J, Jackson AP (2009) 17q21.31 microdeletion syndrome: further expanding the clinical phenotype. Cytogenet Genome Res 127(1):61–66. doi:10.1159/000279260
36. Iwata A, Nagata K, Hatsuta H, Takuma H, Bundo M, Iwamoto K, Tamaoka A, Murayama S et al (2014) Altered CpG methylation in sporadic Alzheimer's disease is associated with APP and MAPT dysregulation. Hum Mol Genet 23(3):648–656. doi:10.1093/hmg/ddt451
37. Coupland KG, Mellick GD, Silburn PA, Mather K, Armstrong NJ, Sachdev PS, Brodaty H, Huang Y et al (2014) DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro. Mov Disord 29(13):1606–1614. doi:10.1002/mds.25784
38. Delay C, Mandemakers W, Hebert SS (2012) MicroRNAs in Alzheimer's disease. Neurobiol Dis 46(2):285–290. doi:10.1016/j.nbd.2012.01.003
39. Li Y, Chen JA, Sears RL, Gao F, Klein ED, Karydas A, Geschwind MD, Rosen HJ et al (2014) An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy. PLoS Genet 10(3), e1004211. doi:10.1371/journal.pgen.1004211
40. Abe M, Bonini NM (2013) MicroRNAs and neurodegeneration: role and impact. Trends Cell Biol 23(1):30–36. doi:10.1016/j.tcb.2012.08.013
41. Tan L, Yu JT, Tan L (2014) Causes and Consequences of MicroRNA Dysregulation in Neurodegenerative Diseases. Molecular neurobiology. doi:10.1007/s12035-014-8803-9.
42. Santa-Maria I, Alaniz ME, Renwick N, Cela C, Fulga TA, Van Vactor D, Tuschl T, Clark LN et al (2015) Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J Clin Invest 125(2):681–686. doi:10.1172/JCI78421
43. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118(1):53–69. doi:10.1007/s00401-009-0486-3
44. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT (2010) Caspase activation precedes and leads to tangles. Nature 464(7292):1201–1204. doi:10.1038/nature08890
45. Wang ZX, Tan L, Yu JT (2015) Axonal transport defects in Alzheimer's disease. Mol Neurobiol 51(3):1309–1321. doi:10.1007/s12035-014-8810-x
46. Iovino M, Agathou S, Gonzalez-Rueda A, Del Castillo Velasco-Herrera M, Borroni B, Alberici A, Lynch T, O'Dowd S, et al. (2015) Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations. Brain: a journal of neurology. doi: 10.1093/brain/awv222
47. Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP (2013) Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 14(4):389–394. doi:10.1038/embor.2013.15
48. Braak H, Del Tredici K (2011) Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol 121(5):589–595. doi:10.1007/s00401-011-0825-z
49. Clavaguera F, Lavenir I, Falcon B, Frank S, Goedert M, Tolnay M (2013) "Prion-like" templated misfolding in tauopathies. Brain Pathol 23(3):342–349. doi:10.1111/bpa.12044
50. Goedert M, Falcon B, Clavaguera F, Tolnay M (2014) Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr Neurol Neurosci Rep 14(11):495. doi:10.1007/s11910-014-0495-z
51. Mohamed NV, Herrou T, Plouffe V, Piperno N, Leclerc N (2013) Spreading of tau pathology in Alzheimer's disease by cell-to-cell transmission. Eur J Neurosci 37(12):1939–1948. doi:10.1111/ejn.12229
52. Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK et al (2014) Neuronal activity regulates extracellular tau in vivo. J Exp Med 211(3):387–393. doi:10.1084/jem.20131685
53. Gomez-Ramos A, Diaz-Hernandez M, Rubio A, Miras-Portugal MT, Avila J (2008) Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol Cell Neurosci 37(4):673–681. doi:10.1016/j.mcn.2007.12.010
54. Maccioni RB, Farias G, Morales I, Navarrete L (2010) The revitalized tau hypothesis on Alzheimer's disease. Arch Med Res 41(3):226–231. doi:10.1016/j.arcmed.2010.03.007
55. Li Y, Tan MS, Jiang T, Tan L (2014) Microglia in Alzheimer's disease. BioMed Res Int 2014:437483. doi:10.1155/2014/437483
56. Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, Luebke JI, Koffie RM, Frosch MP et al (2011) Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol 179(4):2071–2082. doi:10.1016/j.ajpath.2011.07.004
57. Manczak M, Reddy PH (2012) Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet 21(11):2538–2547. doi:10.1093/hmg/dds072
58. DuBoff B, Gotz J, Feany MB (2012) Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron 75(4):618–632. doi:10.1016/j.neuron.2012.06.026
59. Quintanilla RA, Dolan PJ, Jin YN, Johnson GV (2012) Truncated tau and Abeta cooperatively impair mitochondria in primary neurons. Neurobiology of aging 33 (3):619 e625-635. doi:10.1016/j.neurobiolaging.2011.02.007
60. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R (2011) Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 6:39. doi:10.1186/1750-1326-6-39
61. Melov S, Adlard PA, Morten K, Johnson F, Golden TR, Hinerfeld D, Schilling B, Mavros C et al (2007) Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One 2(6), e536. doi:10.1371/journal.pone.0000536
62. Verri M, Pastoris O, Dossena M, Aquilani R, Guerriero F, Cuzzoni G, Venturini L, Ricevuti G et al (2012) Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease. Int J Immunopathol Pharmacol 25(2):345–353
63. Wang ZX, Tan L, Liu J, Yu JT (2015) The Essential Role of Soluble Abeta Oligomers in Alzheimer's Disease. Molecular neurobiology. doi:10.1007/s12035-015-9143-0
64. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC et al (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142(3):387–397. doi:10.1016/j.cell.2010.06.036
65. Salter MW, Kalia LV (2004) Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci 5(4):317–328. doi:10.1038/nrn1368
66. Bhaskar K, Yen SH, Lee G (2005) Disease-related modifications in tau affect the interaction between Fyn and Tau. J Biol Chem 280(42):35119–35125. doi:10.1074/jbc.M505895200
67. Quintanilla RA, von Bernhardi R, Godoy JA, Inestrosa NC, Johnson GV (2014) Phosphorylated tau potentiates Abeta-induced mitochondrial damage in mature neurons. Neurobiol Dis 71:260–269. doi:10.1016/j.nbd.2014.08.016
68. Lagunes T, Herrera-Rivero M, Hernandez-Aguilar ME, Aranda-Abreu GE (2014) Abeta(1–42) induces abnormal alternative splicing of tau exons 2/3 in NGF-induced PC12 cells. An Acad Bras Cienc 86(4):1927–1934. doi:10.1590/0001-3765201420130333
69. Oliveira JM, Henriques AG, Martins F, Rebelo S, da Cruz ESOA (2015) Amyloid-beta Modulates Both AbetaPP and Tau Phosphorylation. Journal of Alzheimer's disease: JAD. doi:10.3233/JAD-142664
70. Xu H, Rosler TW, Carlsson T, de Andrade A, Fiala O, Hollerhage M, Oertel WH, Goedert M et al (2014) Tau Silencing by siRNA in the P301S Mouse model of Tauopathy. Curr Gene Ther 14(5):343–51
71. DeVos SL, Miller TM (2013) Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics 10(3):486–497. doi:10.1007/s13311-013-0194-5
72. Sud R, Geller ET, Schellenberg GD (2014) Antisense-mediated exon skipping decreases Tau protein expression: a potential therapy for Tauopathies. Molecular Therapy Nucleic Acids 3, e180. doi:10.1038/mtna.2014.30
73. Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP (2015) Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol 55:353–371. doi:10.1146/annurev-pharmtox-010814-124332
74. Tortosa E, Santa-Maria I, Moreno F, Lim F, Perez M, Avila J (2009) Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J Alzheimers Dis 17(2):319–325. doi:10.3233/JAD-2009-1049
75. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, Gestwicki JE, Dickey CA et al (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8(4):609–622. doi:10.4161/auto.19048
76. Shimada K, Motoi Y, Ishiguro K, Kambe T, Matsumoto SE, Itaya M, Kunichika M, Mori H et al (2012) Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion. Neurobiol Dis 46(1):101–108. doi:10.1016/j.nbd.2011.12.050
77. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F (2006) Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 99(6):1445–1455. doi:10.1111/j.1471-4159.2006.04139.x
78. Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, Frolich L, Schroder J et al (2009) Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70(6):922–931
79. Sereno L, Coma M, Rodriguez M, Sanchez-Ferrer P, Sanchez MB, Gich I, Agullo JM, Perez M et al (2009) A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 35(3):359–367. doi:10.1016/j.nbd.2009.05.025
80. Lovestone S, Boada M, Dubois B, Hull M, Rinne JO, Huppertz HJ, Calero M, Andres MV et al (2015) A phase II trial of Tideglusib in Alzheimer's disease. J Alzheimers Dis 45(1):75–88. doi:10.3233/JAD-141959
81. Tolosa E, Litvan I, Hoglinger GU, Burn D, Lees A, Andres MV, Gomez-Carrillo B, Leon T et al (2014) A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 29(4):470–478. doi:10.1002/mds.25824
82. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402(6762):615–622. doi:10.1038/45159
83. Piedrahita D, Hernandez I, Lopez-Tobon A, Fedorov D, Obara B, Manjunath BS, Boudreau RL, Davidson B et al (2010) Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice. J Neurosci 30(42):13966–13976. doi:10.1523/JNEUROSCI.3637-10.2010
84. Cho DH, Lee EJ, Kwon KJ, Shin CY, Song KH, Park JH, Jo I, Han SH (2013) Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons. J Neurochem 126(5):685–695. doi:10.1111/jnc.12264
85. Chu J, Pratico D (2013) 5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5. Neurobiol Aging 34(6):1549–1554. doi:10.1016/j.neurobiolaging.2012.12.009
86. Sundaram JR, Poore CP, Sulaimee NH, Pareek T, Asad AB, Rajkumar R, Cheong WF, Wenk MR et al (2013) Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo. J Neurosci 33(1):334–343. doi:10.1523/JNEUROSCI.3593-12.2013
87. Rao MV, McBrayer MK, Campbell J, Kumar A, Hashim A, Sershen H, Stavrides PH, Ohno M et al (2014) Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. J Neurosci 34(28):9222–9234. doi:10.1523/jneurosci.1132-14.2014
88. Wu J, Tolstykh T, Lee J, Boyd K, Stock JB, Broach JR (2000) Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo. EMBO J 19(21):5672–5681. doi:10.1093/emboj/19.21.5672
89. Li W, Jiang M, Xiao Y, Zhang X, Cui S, Huang G (2015) Folic acid inhibits tau phosphorylation through regulation of PP2A methylation in SH-SY5Y cells. J Nutr Health Aging 19(2):123–129. doi:10.1007/s12603-014-0514-4
90. Yang CC, Kuai XX, Li YL, Zhang L, Yu JC, Li L, Zhang L (2013) Cornel Iridoid glycoside attenuates Tau Hyperphosphorylation by inhibition of PP2A Demethylation. Evidence-based Complementary Alternative Med: eCAM 2013:108486. doi:10.1155/2013/108486
91. Chohan MO, Khatoon S, Iqbal IG, Iqbal K (2006) Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine. FEBS Lett 580(16):3973–3979. doi:10.1016/j.febslet.2006.06.021
92. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, Parsons CG, Gupta S et al (2010) Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 176(2):870–880. doi:10.2353/ajpath.2010.090452
93. McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Systematic Rev 2:CD003154. doi:10.1002/14651858.CD003154.pub5
94. van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Gotz J, Ittner LM (2010) Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci U S A 107(31):13888–13893. doi:10.1073/pnas.1009038107
95. Cheng XS, Zhao KP, Jiang X, Du LL, Li XH, Ma ZW, Yao J, Luo Y et al (2013) Nmnat2 attenuates Tau phosphorylation through activation of PP2A. J Alzheimers Dis 36(1):185–195. doi:10.3233/JAD-122173
96. Chang E, Honson NS, Bandyopadhyay B, Funk KE, Jensen JR, Kim S, Naphade S, Kuret J (2009) Modulation and detection of tau aggregation with small-molecule ligands. Curr Alzheimer Res 6(5):409–414
97. Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, Hasegawa M (2005) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 280(9):7614–7623. doi:10.1074/jbc.M408714200
98. Daccache A, Lion C, Sibille N, Gerard M, Slomianny C, Lippens G, Cotelle P (2011) Oleuropein and derivatives from olives as Tau aggregation inhibitors. Neurochem Int 58(6):700–707. doi:10.1016/j.neuint.2011.02.010
99. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 93(20):11213–11218
100. van Bebber F, Paquet D, Hruscha A, Schmid B, Haass C (2010) Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiol Dis 39(3):265–271. doi:10.1016/j.nbd.2010.03.023
101. Spires-Jones TL, Friedman T, Pitstick R, Polydoro M, Roe A, Carlson GA, Hyman BT (2014) Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neurosci Lett 562:63–68. doi:10.1016/j.neulet.2014.01.013
102. Wischik C, Staff R (2009) Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging 13(4):367–369
103. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM (2011) Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 6(12), e26860. doi:10.1371/journal.pone.0026860
104. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J et al (2011) Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 286(39):34457–34467. doi:10.1074/jbc.M111.229633
105. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S et al (2012) Targeting phospho-Ser422 by active Tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9(4):397–405
106. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27(34):9115–9129. doi:10.1523/JNEUROSCI.2361-07.2007
107. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118(4):658–667. doi:10.1111/j.1471-4159.2011.07337.x
108. Boutajangout A, Quartermain D, Sigurdsson EM (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30(49):16559–16566. doi:10.1523/JNEUROSCI.4363-10.2010
109. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224(2):472–485. doi:10.1016/j.expneurol.2010.05.010
110. Gu J, Congdon EE, Sigurdsson EM (2013) Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem 288(46):33081–33095. doi:10.1074/jbc.M113.494922
111. Krishnamurthy PK, Deng Y, Sigurdsson EM (2011) Mechanistic studies of antibody-mediated clearance of Tau Aggregates using an ex vivo brain slice model. Frontiers Psychiatry 2:59. doi:10.3389/fpsyt.2011.00059
112. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T et al (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53(3):337–351. doi:10.1016/j.neuron.2007.01.010
113. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN et al (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 95(18):10896–10901
114. Nash KR, Lee DC, Hunt JB Jr, Morganti JM, Selenica ML, Moran P, Reid P, Brownlow M et al (2013) Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol Aging 34(6):1540–1548. doi:10.1016/j.neurobiolaging.2012.12.011
115. Yoshiyama Y, Kojima A, Ishikawa C, Arai K (2010) Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J Alzheimers Dis 22(1):295–306. doi:10.3233/JAD-2010-100681
116. Cai Z, Yan Y, Wang Y (2013) Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder. Clin Interv Aging 8:1089–1095. doi:10.2147/CIA.S46536
117. Kurata T, Lukic V, Kozuki M, Wada D, Miyazaki K, Morimoto N, Ohta Y, Deguchi K et al (2014) Telmisartan reduces progressive accumulation of cellular amyloid beta and phosphorylated tau with inflammatory responses in aged spontaneously hypertensive stroke resistant rat. J Stroke Cerebrovasc Dis 23(10):2580–2590. doi:10.1016/j.jstrokecerebrovasdis.2014.05.023
118. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, Iba M, James MJ et al (2010) Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 30(41):13861–13866. doi:10.1523/JNEUROSCI.3059-10.2010
119. Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AM, Xie SX et al (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 32(11):3601–3611. doi:10.1523/JNEUROSCI.4922-11.2012
120. Barten DM, Fanara P, Andorfer C, Hoque N, Wong PY, Husted KH, Cadelina GW, Decarr LB et al (2012) Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J Neurosci 32(21):7137–7145. doi:10.1523/JNEUROSCI.0188-12.2012
121. Gozes I (2011) NAP (davunetide) provides functional and structural neuroprotection. Curr Pharm Des 17(10):1040–1044
122. Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I (2009) NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 34(2):381–388. doi:10.1016/j.nbd.2009.02.011
123. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A et al (2014) Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 13(7):676–685. doi:10.1016/S1474-4422(14)70088-2
124. Zhou J, Yu Q, Zou T (2008) Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies. BMC Neurosci 9(Suppl 2):S10. doi:10.1186/1471-2202-9-S2-S10
125. Peacey E, Rodriguez L, Liu Y, Wolfe MS (2012) Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing. Nucleic Acids Res 40(19):9836–9849. doi:10.1093/nar/gks710
126. Nygaard HB, van Dyck CH, Strittmatter SM (2014) Fyn kinase inhibition as a novel therapy for Alzheimer's disease. Alzheimers Res Ther 6(1):8. doi:10.1186/alzrt238
127. Kaufman AC, Salazar SV, Haas LT, Yang J, Kostylev MA, Jeng AT, Robinson SA, Gunther EC, et al. (2015) Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Annals of neurology. doi:10.1002/ana.24394
128. Hampton DW, Webber DJ, Bilican B, Goedert M, Spillantini MG, Chandran S (2010) Cell-mediated neuroprotection in a mouse model of human tauopathy. J Neurosci 30(30):9973–9983. doi:10.1523/JNEUROSCI.0834-10.2010
129. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, Yamasaki TR, Poon WW et al (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A 106(32):13594–13599. doi:10.1073/pnas.0901402106